Habil Khorakiwala says: “We have earlier signed an agreement on a profit-sharing basis for contract manufacturing with Serum Institute to make vaccines in our UK facility. This is a long 15-year agreement and we have earmarked capacity for 150 million doses for them. We are also in discussion with a global vaccine company for contract manufacturing opportunities.”
Related Keywords
China , India , Japan , United States , Lucknow , Uttar Pradesh , United Kingdom , , Wockhardt Group , Offering College , Indian School Of Business , Serum Institute , Habil Khorakiwala , Drug Controller , Leadership Excellence , Operations Officer , Might Also Like , Nafithromycin Launch , Clinical Trial Completion , Meropenem Resistance Cases , Wockhardt , Oncea Day Antibiotic , Expert View , Stock Market , Et Now ,
comparemela.com © 2020. All Rights Reserved.